Biotechnology

The Selux PBC Separator With Selux AST System Receives FDA 510(k) Clearance for Rapid Antibiotic Susceptibility Testing Direct From Positive Blood Culture

February 26, 2024 9:30 AM

The Selux PBC Separator, part of the Next Generation Phenotyping (NGP) System, makes this the only FDA cleared, single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies. BOSTON, MA / ACCESSWIRE / February 26, 2024 / Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and preserve the lifesaving power of antibiotics for future generations,...

Read more

MRES: M2Bio Sciences Introduces M2BioKids: A Pioneering Approach to Elevating Childhood Health and Development

February 23, 2024 9:20 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 23, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates: M2Bio Sciences proudly announces the launch of its...

Read more

MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward

February 22, 2024 9:15 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology,specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edgemental health therapeutic research driven by artificial intelligence (AI), is pleased to sharethe following M2Enviro updates: M2Enviro, at the forefront of biotechnological...

Read more

BioInvent International AB Year-end Report January 1 - December 31, 2023

February 22, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / February 22, 2024 / BioInvent International (STO:BINV) "2023 was a landmark year for BioInvent with positive clinical readouts from three Phase 1/2 programs. These data, supported by validating partnerships, a strong cash position and solid investor base, set BioInvent up to have a breakout year in 2024, fueled by expectations for substantial clinical progress across our pipeline." - Martin Welschof, CEO of BioInvent....

Read more

Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023

February 22, 2024 1:20 AM

Organic revenue growth in 2023: +10.4% Organic adjusted EBITDA growth in 2023: +17.5% Favorable product mix boosts profitability High order backlog and global capacity expansion secure profitable growth for the years ahead DUSSELDORF, GERMANY / ACCESSWIRE / February 22, 2024 / Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, decisively continued on its profitable...

Read more

IMBIOTECHNOLOGIES Signs Supply Agreement Embol Experts

February 21, 2024 10:25 AM

EDMONTON, AB / ACCESSWIRE / February 21, 2024 / IMBiotechnologies Ltd. ("IMBiotechnologies") is pleased to announce the signing of a supply agreement with Embol Experts, LLC ("Embol Experts"), one of the largest group purchasing organizations (GPOs) in the US, supplying office-based laboratory (OBL) and ambulatory surgical center (ASC) clinics focused on minimally-invasive procedures. "We are excited to be working with IMBiotechnologies as their...

Read more

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

February 21, 2024 8:00 AM

~ PF614-MPAR program receives FDA guidance ~ SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, is providing an update following its recent meeting with the Food and Drug Administration (FDA) regarding its second product, a ‘Next Generation' opioid analgesic with overdose protection,...

Read more

New U Hair(TM) Unveils Revolutionary TrichoBioScan(TM): Experts Calling It Key to Unlocking One’s Unique Hair Loss Mysteries

February 20, 2024 10:00 AM

A Scientific Personalized Approach Poised to Revolutionize How People Combat Hair Loss TAMPA, FL / ACCESSWIRE / February 20, 2024 / New U Hair™, a national leading pioneer in preventative healthcare solutions since 2007, proudly announces the launch of its groundbreaking TrichoBioScan™. This state-of-the art diagnostic tool is set to redefine the approach to combatting hair loss at its root cause, offering individuals a chance to understand the...

Read more

Prolocor to Present New Clinical Evidence at ACC 24 Supporting the Use of PLATELET FCɣRIIA (PFCG) as a Key Tool in Individualizing Dual Antiplatelet Therapy (DAPT)

February 20, 2024 9:00 AM

Date April 6, 2024, Location Hall B4-5 Abstract 1307-159 / 159 ASSOCIATION BETWEEN PROGNOSTIC IMPLICATIONS OF PLATELET FCɣRIIA (PFCG) AND TREATMENT STRATEGY FOR MYOCARDIAL INFARCTION PHILADELPHIA, PA / ACCESSWIRE / February 20, 2024 / Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the goal of predicting the risk of thrombosis by quantifying platelet FcγRIIa (pFCG test), today announced the acceptance...

Read more

Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024

February 20, 2024 8:30 AM

IRVINE, CA / ACCESSWIRE / February 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 American Venous Forum (AVF) Annual Meeting being held March 3-6, 2024 in Tampa, Florida. The presentation will be made on Wednesday, March 6,...

Read more

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

February 20, 2024 8:10 AM

Ameluz ® transfer price to Biofrontera AG reduced significantly Control of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1 WOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced the restructuring of agreements between the Company and its former parent company...

Read more

Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules

February 20, 2024 8:05 AM

Company secures financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth WOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company") , a...

Read more

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

February 20, 2024 8:01 AM

Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studies Phase 1 clinical trial compared oral transmucosal delivery of TH104 to injectable reference approved drug completed Company fully funded into 2025 with Phase 2 moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC) study on-track and expected to initiate in 2024 BRIDGEWATER, NJ / ACCESSWIRE /...

Read more

Invitation to Presentation of BioInvent’s Year-end Report 2023

February 20, 2024 4:30 AM

LUND, SE / ACCESSWIRE / February 20, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the year-end report 2023 at 2:00 pm on February 22. The report will be published at 8:00 am CET the same day. BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English. When: Thursday February 22, 2024,...

Read more

Hyris Technology Supports the Fight Against One of the World’s Deadliest Diseases, Malaria

February 20, 2024 3:00 AM

Hyris' molecular diagnostic technology has been adapted to enable real-time surveillance of mosquito vector insecticide resistance, which will aid in malaria control campaigns. LONDON, UK / ACCESSWIRE / February 20, 2024 / Hyris, working with an international team of researchers, has developed a prototype field-deployable surveillance system to detect insecticide-resistant malaria vector mosquitoes in the field without the need for...

Read more

Enalare Therapeutics Announces Publication of a Clinical Study Demonstrating the Effect of ENA-001 on Improving Propofol-Induced Depression of the Hypoxic Ventilatory Response

February 15, 2024 8:00 AM

PRINCETON, NJ / ACCESSWIRE / February 15, 2024 / Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health emergencies, today announced the publication of a respiratory depression study with its lead compound, ENA-001 in the journal Anesthesiology. The article entitled "Reversal of Propofol-induced Depression of...

Read more

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

February 15, 2024 8:00 AM

KELOWNA, BC / ACCESSWIRE / February 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.31 per share (or per common stock equivalent in lieu thereof) in a...

Read more

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider

February 14, 2024 9:15 AM

AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counter NEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces a new partnership with a leading, multi-billion-dollar AI software provider to adapt its technology for...

Read more

Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders

February 13, 2024 8:30 AM

Company Anticipates Reporting Complete Phase I Single Dose Results in April NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced a step forward in its mission to address stress-related neuro-psychiatric disorders. The company has completed the first dose escalation step in the Phase I safety clinical trial for PT00114, its pioneering brain peptide compound. The...

Read more

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

February 13, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,601,752 shares of common stock of the Company originally...

Read more